Categories |
|
Generics |
|
Biotechnology
Cancer
Consumer
Customer Relationship Management
Drug Delivery
eHealthcare Pharma
eHealthcare Physician
Generics
Healthcare
Medical Devices
OTC Pharmaceuticals
Pharmaceuticals
Pharmacoeconomics
Therapeutic Areas:
- Cardiovascular
- Central Nervous System
- Immune Disorders and Inflammation
- Infectious Diseases
- Oncology
- Women'sHealth
|
|
|
1- European Market Entry Strategies: Impact of Regulations, Pricing, Reimbursement, Parallel Trade and Generics Post-Accession (Executive Summary in Japanese)
15-Apr-2004
Investigation of strategies for successful market entry into the EU, now and after the accession of 10 new member states on 1 May 2004.
------------------------------------------------------------------------------------------------------------------------- |
2- European Market Entry Strategies: Impact of Regulations, Pricing, Reimbursement, Parallel Trade and Generics Post-Accession 15-Dec-2003
Investigation of strategies for successful market entry into the EU, now and after the accession of 10 new member states on 1 May 2004.
-------------------------------------------------------------------------------------------------------------------------
|
3- Global Generics Guide 2nd Edition: Optimizing geographical and strategic positioning in an evolving generics landscape 11-Dec-2003
Analysis of the global generics market, emphasizing key features of EU versus US markets. Includes discussion of drivers of generics market expansion, with profiles of 11 key players, with six year forecasts charting portfolio development.
------------------------------------------------------------------------------------------------------------------------- |
4- The European Generics Outlook: A country-by-country analysis of developing market opportunities and revenue defense strategies 29-Apr-2003
The report provides detailed insights into European market dynamics, and explores strategies for survival for generic companies and defense strategies for multinationals' branded drugs.
------------------------------------------------------------------------------------------------------------------------- |
| |
